The study focused on retired athletes because retirement from sport can involve changes in athletic identity, self-worth, and body-image concerns. Although self-compassion meditation has improved self-compassion and body appreciation and reduced body shame and appearance-based self-worth in other populations, it had not previously been studied with retired athletes. The trial therefore tested whether a brief online intervention could be delivered, accepted, and sustained in this group, rather than establishing whether it is an effective treatment.

Participants were randomized to the meditation program or a waitlist control group. The intervention lasted 21 days and consisted of three audio-based self-compassion practices delivered online. It was self-guided, allowing participants to complete the exercises independently.

Researchers assessed acceptability through thematic analysis of open-ended responses, measured retention as the proportion who completed the intervention, and tracked recruitment as enrollment over time. Retention was considered appropriate at 76%, and qualitative findings suggested that participants found the program acceptable. They described greater awareness of their bodies and more positive shifts in how they perceived themselves.

Recruitment, however, was modest at 10 participants per month. The study was not preregistered, and its sample of 37 retired athletes limits the strength of conclusions about the intervention’s effects. Secondary outcomes included self-compassion, body dissatisfaction, body shame, body appreciation, and appearance-contingent self-worth.

ANCOVAs controlling for baseline values were used to examine these measures. Participants who completed the program showed signs of improvement in body appreciation and self-compassion, along with potential reductions in body dissatisfaction, body shame, and appearance-based self-worth. These are preliminary signals from a feasibility trial, not definitive evidence that the program caused lasting psychological changes or provided clinical benefit.

Overall, the findings indicate that a short, self-guided meditation program can engage many retired athletes who are concerned about their body image. The strongest evidence concerns feasibility and acceptability: most enrolled participants completed the program, and their comments described positive experiences and stronger body awareness. The results also identify recruitment as a practical constraint.

The authors concluded that self-compassion may be a promising approach for supporting body image and psychological adaptation during retirement from sport, and that the next step is a larger, fully powered randomized controlled trial.

Subject of Research: Feasibility of online self-compassion meditation for body-image concerns among retired athletes

Article Title: A Study Evaluating the Feasibility of a Self-compassion Meditation on Body Image in Retired Athletes

Article References: Hough, S. B. E., Smart, C. M., & Rhodes, R. E. (2026). A Study Evaluating the Feasibility of a Self-compassion Meditation on Body Image in Retired Athletes. Mindfulness. https://doi.org/10.1007/s12671-026-02999-0

Image Credits: AI Generated

DOI: 10.1007/s12671-026-02999-0

Keywords: self-compassion, meditation, retired athletes, body image, mindfulness, feasibility trial, online intervention, psychological adaptation, randomized trial, Evaluating, Feasibility, Body

The trial, funded through the National Institute on Drug Abuse’s Clinical Trials Network, tested a model called PrIMO, short for pharmacist-integrated medication treatment for opioid use disorder. The model grew out of work at Penobscot Community Health Care, Maine’s largest federally qualified health center, which had previously woven clinical pharmacists into its primary care addiction services and seen reductions in overdose mortality alongside increases in prescribing. The new study asked whether that success could be replicated in four diverse primary care sites across the Northeast, Midwest, Northwest, and Southwest of the United States between August 2022 and July 2024.

PrIMO rests on six core components: collaborative communication among team members, weekly huddles with active clinical decision-making for all patients with opioid use disorder, provider education, patient education, comorbidity screening, and education for local partners. Pharmacists contribute medication expertise such as managing drug interactions, adjusting doses, and handling prior authorizations, while also consulting directly with patients in partnership with prescribers. Crucially, the model was designed to use existing pharmacists rather than requiring new hires, and a toolkit plus monthly meetings with model developers and external facilitators helped each site maintain fidelity while tailoring the approach to its own context.

The primary outcome was feasibility, measured with the Stages of Implementation Completion, an eight-stage tool tracking sixty-one milestones from initial engagement through site competency. All four sites, two federally qualified health centers and two based at academic medical centers, successfully launched PrIMO, a 100 percent launch rate, and all maintained it for at least one year. Launch times ranged from 381 days at the fastest site to 586 days at the slowest, and the clinics completed an average of 85.3 percent of milestones. Readiness planning proved the hardest stage, completed at only 62.8 percent, likely reflecting how busy clinical teams prioritize patient care over administrative infrastructure. By fifteen months post-launch, all but one site was still running the model, and two had expanded it to additional care teams.

Acceptability, assessed through surveys and interviews with 91 staff members and 56 patients, was moderate overall and held steady over time. Staff reported increased knowledge of medications for opioid use disorder, with mean scores rising from 3.8 to 4.0 on a five-point scale, and fewer perceived barriers to providing treatment, dropping from 2.2 to 1.8 on a four-point scale. Patients reported a decline in internalized stigma, from 3.1 to 2.8 on a five-point scale. Qualitative interviews reinforced the quantitative picture. Staff described the model as aligned with clinic values and uncomplicated, with one noting that breaking down silos made care easier for everybody. Patients reported few challenges starting or continuing treatment, with one saying their care had improved under the new model.

Fidelity monitoring showed the core components were delivered at levels sufficient for early-stage research. Weekly huddles occurred 82 percent of the time, 78 percent of patients were screened for comorbid conditions, and provider education was continuous. The cost of implementation was tracked using a method that maps staff hours to Bureau of Labor Statistics salaries. On average, sites invested 172.25 hours over fifteen months, at an estimated cost of $18,405, well below the roughly $40,778 average reported for similar collaborative care implementations. No new hires were needed, including pharmacists, and the model fit into existing workflows.

Electronic health record data from one year before versus one year after launch showed encouraging signals, though the exploratory design did not test statistical significance. The proportion of days covered, a measure of treatment retention, edged up from 59.5 to 60.2 percent, and the share of patients achieving adherence above 80 percent of days covered rose from 38.6 to 40.9 percent. Clinic visits for opioid use disorder increased by 100 encounters, and the average number of patients treated per prescriber rose from 12.9 to 13.7. Notably, two sites lost prescribers during the study yet maintained or increased patient volume, suggesting the model may build provider confidence and efficiency. Urine toxicology showed diminished co-occurring use of several substances, including fentanyl, which fell from 9.2 to 7.2 percent of tests.

The researchers are careful about limitations. The study involved only four clinics without a control condition, and all sites were established treatment providers with retail pharmacies, 340B drug pricing membership, and multiple medication offerings, characteristics that may have boosted acceptability scores. The observed drop in patient stigma, while encouraging, cannot be attributed to the model specifically. Enrollment was restricted to English speakers, urine testing protocols varied across sites, and the project’s time-limited nature prevented a true assessment of long-term sustainability. Still, the geographic, organizational, and size diversity of the sites strengthens the case that the model can travel beyond its rural Maine origins.

The implications are significant. Pharmacists are among the most accessible clinicians in the health care system, yet pharmacist-led interventions for opioid use disorder remain underutilized. This trial provides the first data demonstrating that integrating pharmacists into primary care addiction teams is feasible across varied settings, acceptable to both staff and patients, and achievable without new hires or workflow restructuring. As the overdose crisis continues to demand what researchers call an all-hands-on-deck response, PrIMO offers a pragmatic, relatively inexpensive blueprint for expanding the workforce capable of delivering lifesaving medication, with a more rigorous effectiveness trial planned to determine just how far these promising early results can go.

Subject of Research: A nonrandomized clinical trial evaluating the feasibility and acceptability of a pharmacist-integrated collaborative care model for opioid use disorder in primary care settings.

Article Title: Feasibility of Implementing a Pharmacist-Integrated Collaborative Model for Opioid Use Disorder: A Nonrandomized Clinical Trial

Article References: Homsted, F., Fiellin, D. A., Ghitza, U. E., Gardner, V. T., III, McLeman, B., Joudrey, P. J., Cochran, G., Moore, S. K., Saldana, L., Chongsi, E., Kramer, K., Vena, A., Ottesen, R. A., Harris, J., Boggis, J. S., Rao, D., Murray, O., Gerlach, S., Gauthier, P., … Marsch, L. A. (2026). Feasibility of Implementing a Pharmacist-Integrated Collaborative Model for Opioid Use Disorder: A Nonrandomized Clinical Trial. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10924-3

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10924-3

Keywords: opioid use disorder, pharmacists, primary care, medications for opioid use disorder, buprenorphine, implementation science, PrIMO, collaborative care, feasibility trial, treatment retention, stigma, health services research

The rationale for turning to nature rests on a growing but still incomplete body of evidence. Conventional care for ADHD typically relies on medication and, in some cases, parent training or cognitive behavioural approaches, yet post-diagnostic support within NHS services remains inconsistent and often stretched thin. Nature-based interventions, which involve guided activities in green or natural settings, have shown promise for mental wellbeing across a range of populations, but they remain under-researched specifically for children with ADHD as an adjunct to standard treatment. The CONIFAS2 team argues that this evidence gap matters, because families need timely, accessible options that complement rather than replace existing care. By embedding the intervention within NHS neurodiversity services rather than treating it as a standalone lifestyle recommendation, the researchers hope to test something that could realistically become part of routine clinical practice.

A distinctive feature of the study is its co-production ethos. Rather than designing the intervention behind closed doors and presenting it to families as a finished product, the researchers developed the programme collaboratively with the people who will actually use it, including children with lived experience of ADHD, their parents, and NHS practitioners. Co-production of this kind is increasingly recognised in health services research as a way to ensure that interventions are not only theoretically sound but also practical, culturally appropriate, and engaging for the families expected to complete them. For a population in which daily routines are often difficult to sustain, the difference between an activity schedule that feels imposed and one that families helped to shape could determine whether the programme is followed at all.

The design of the trial itself follows the established architecture of a feasibility study. Children who have received a diagnosis of ADHD and their parent or guardian will be recruited as a dyad, meaning the pair is treated as the unit of participation, from NHS neurodiversity services. This dyad structure reflects the reality that a home-based intervention for a child necessarily involves parental support and supervision. After completing a baseline assessment, each dyad will be randomised to one of two arms. The intervention arm receives a programme of structured daily nature-based activities accompanied by psychoeducational support, delivered alongside usual treatment. The control arm receives treatment as usual only. Randomisation ensures that differences observed between the groups in engagement, outcomes, or data completeness can be attributed to the intervention pathway rather than to pre-existing differences between families.

What exactly does the intervention involve? The protocol describes structured daily nature-based activities, which in practice means deliberately planned engagements with the natural environment carried out at or near home, paired with psychoeducational components that help children and parents understand ADHD and the reasoning behind the activities. The home-based delivery model is a deliberate choice with important implications for equity and scalability. Clinic-based programmes often exclude families who cannot travel regularly, whereas a home-based format could, in principle, reach a much broader population. At the same time, home delivery raises its own questions about fidelity, which is the technical term for whether the intervention is delivered as intended. A family that completes only a fraction of the prescribed activities, or completes them in a substantially altered form, weakens the researchers’ ability to interpret results. Assessing intervention fidelity is therefore one of the trial’s explicit feasibility objectives.

The primary purpose of CONIFAS2 is to measure feasibility and acceptability across several dimensions. The team will track recruitment, asking whether enough eligible dyads can be enrolled through NHS services and whether the recruitment pathway itself functions smoothly. They will measure retention, meaning how many families remain in the trial from baseline through follow-up, a critical concern in any study requiring sustained daily activity from children with a condition characterised by difficulties with attention and routine. They will also evaluate whether the planned data collection procedures work in practice, and whether both the intervention and the trial design are acceptable to participants. Acceptability is not a soft outcome; interventions that families find burdensome, stigmatising, or impractical fail in real-world implementation regardless of what efficacy trials suggest.

Beyond the core feasibility outcomes, the study incorporates a mixed methods process evaluation, a design element that separates thoughtful feasibility work from simple pilot testing. Quantitative data alone can show that families dropped out or failed to complete activities, but they cannot explain why. The process evaluation will combine qualitative and quantitative approaches to refine a programme theory, essentially a structured account of how the intervention is supposed to produce its effects, and to identify the barriers and facilitators that shape delivery, engagement, and eventual implementation. Interviews and other qualitative methods can reveal, for example, whether parents struggled with time constraints, whether children found particular activities motivating or tedious, and whether NHS staff encountered practical obstacles in referring families. These insights directly inform the design of a future definitive trial, potentially saving substantial resources by preventing a large-scale study built on flawed assumptions.

The protocol also includes a feasibility health economic evaluation, an element that reflects the growing expectation that health interventions demonstrate value for money as well as clinical benefit. Before a full cost-effectiveness analysis can be conducted in a definitive trial, researchers must establish that the necessary data can actually be collected from participating families. The CONIFAS2 team will therefore assess the feasibility of gathering information on resource use, such as contacts with health services and use of medications, on costs, and on health-related quality of life. If families find these questionnaires too burdensome or the data too incomplete, a future economic evaluation would be unreliable, and this needs to be known before a large trial commits resources to it. Health-related quality of life measures are particularly important because they allow the benefits of an intervention to be compared across different conditions and treatments using a common metric.

The study is registered with the ISRCTN trial registry under identifier ISRCTN15490570, providing transparency about its design before results are known. The research team brings together expertise spanning environmental science, health sciences, health economics, and clinical practice, with authors including Peter A. Coventry, Piran C. L. White, Sarah Sumpter, Susan Griffin, Chao Huang, and Hannah A. Armitt, among others, reflecting the genuinely interdisciplinary nature of nature-based health research. This breadth matters because such interventions sit at the intersection of environmental psychology, paediatric healthcare, and health service delivery, and no single discipline can evaluate them alone.

The implications of this work extend well beyond ADHD. If CONIFAS2 demonstrates that a co-produced, home-based nature intervention can be feasibly delivered through NHS neurodiversity services, it would clear the path for a definitive trial capable of establishing clinical and cost-effectiveness. More broadly, the study exemplifies a methodological trend in health research: testing deliverability and acceptability rigorously before investing in large efficacy trials, and involving patients and families as genuine partners in intervention design. For the families of children with ADHD who currently face long waits and limited post-diagnostic options, the prospect of a low-cost, accessible support programme built around daily contact with the natural world is an appealing one. The findings, which will be disseminated through peer-reviewed publications, conference presentations, and community partners, will determine whether that prospect advances toward the rigorous evidence needed to change clinical practice.

Subject of Research: Feasibility of a co-produced home-based nature-based intervention for children with ADHD

Article Title: CO-produced Nature-based Intervention Feasibility for children with ADHD Study: The CONIFAS2 study protocol

Article References: Date, K. L., Cohen, J., Coventry, P. A., Dorey, T., Green, N., Griffin, S., Huang, C., Kingsley, E. N., Marlow, M., Sumpter, S., Twiddy, M., White, P. C. L., Woolley, K., & Armitt, H. A. (2026). CO-produced Nature-based Intervention Feasibility for children with ADHD Study: The CONIFAS2 study protocol. PLOS One, 21(10), e0359206. https://doi.org/10.1371/journal.pone.0359206

Image Credits: AI Generated

DOI: 10.1371/journal.pone.0359206

Keywords: ADHD, children, nature-based intervention, feasibility trial, randomised controlled trial, NHS, co-production, psychoeducation, process evaluation, health economics, PLOS One, neurodiversity

The intervention, abbreviated FREED-M, was developed by researchers at King’s College London and collaborators as an online companion to FREED, which stands for First Episode Rapid Early Intervention for Eating Disorders. The original FREED service was built on a simple clinical insight: the earlier an eating disorder is identified and treated, the better the chances of a full recovery. But services can only treat the people who reach them, and many young adults aged 16 to 25 delay seeking help for months or years, often because they are unsure whether their difficulties are serious enough, feel ashamed, or simply do not know where to start. FREED-M was designed to lower those barriers, providing a self-guided, mobile-optimized experience that encourages users to recognize their difficulties and take early steps toward professional support.

To understand whether the tool actually works the way its designers hoped, the research team embedded a qualitative study within a larger feasibility trial. Of the 72 participants who completed the trial, eleven young people volunteered for optional semi-structured interviews about their experiences using FREED-M and taking part in the study. The interviewees had a mean age of 22.45 years, and 92 percent were female, a demographic profile that reflects the known epidemiology of eating disorders in young adulthood. The researchers then analyzed the interview transcripts using reflexive thematic analysis, a qualitative method in which researchers actively examine how their own perspectives shape the identification of patterns in the data, rather than treating themes as if they simply emerge on their own.

The analysis yielded five key themes, and together they sketch a remarkably coherent picture of what a digital intervention must do to move a young person from silent worry toward help-seeking. The first theme was supporting awareness and early steps towards behavioural change. Participants described how using FREED-M helped them name and acknowledge difficulties with eating that they had previously minimized or explained away. In clinical terms, the tool appeared to function as a mirror, allowing users to see their own patterns reflected in structured content and to recognize that those patterns were significant enough to warrant attention. That moment of recognition is often described as the hinge on which early intervention turns, because a person cannot seek help for a problem they have not yet admitted to having.

The second theme captured a subtle psychological balancing act: balancing self-exploration with orientation towards disclosure to others. Participants valued the fact that FREED-M allowed them to explore their eating difficulties privately and independently, at their own pace and without the pressure of a clinical appointment. At the same time, the intervention did not leave them stranded in that private space. It actively oriented them toward telling other people, whether friends, family members, or professionals, about what they were going through. This dual structure matters because autonomy and connection are often in tension for young people with eating disorders. Many fear that seeking help means surrendering control, and a tool that frames disclosure as something the user chooses, rather than something imposed on them, appears to soften that fear.

The third theme, facilitating informational exposure whilst holding psychological safety, addresses one of the central design challenges in digital mental health. Information about eating disorders is abundant online, but much of it is unregulated, and some of it can be actively harmful, reinforcing disordered thinking rather than challenging it. Participants in this study reported that FREED-M provided information about eating disorders in a way that felt safe, accessible, and carefully calibrated. The intervention exposed them to facts about their condition without overwhelming them or triggering the competitive, shame-laden comparisons that can flourish in less structured online environments. Holding that psychological safety while still delivering substantive psychoeducation is a technical achievement, and it suggests that the tone, pacing, and framing of digital content can matter as much as its accuracy.

The fourth theme focused on the mechanics of self-assessment: enabling structured self-reflection through low-burden assessment. Digital interventions typically ask users to complete questionnaires, and poorly designed assessment can feel like an interrogation or an administrative chore that drives people away. Participants described FREED-M’s assessment components as low-burden, meaning they demanded relatively little effort or emotional cost while still producing meaningful structure for reflection. Structured self-reflection of this kind serves a dual purpose. For the user, it converts vague distress into articulated insight, which is a prerequisite for change. For researchers and clinicians, it generates data that can guide the intervention’s future development and, eventually, its evaluation in a full randomized controlled trial.

The fifth theme was perhaps the most practical: supporting engagement through an accessible, attractive and user-friendly design. Participants spoke positively about the look and feel of the platform, describing it as accessible and attractive. In the crowded landscape of health apps, where abandonment rates are notoriously high, design is not a cosmetic concern but a clinical one. An intervention that a young person finds pleasant to open has a fundamentally different trajectory from one that feels like a medical form. The researchers note that these engagement findings will directly inform future iterations of FREED-M, an iterative development model that is increasingly seen as best practice in digital health, where tools are refined through repeated cycles of user feedback before being tested at scale.

It is important to read these findings with appropriate scientific caution. This was a qualitative study with eleven interviewees, all drawn from people who had already completed a feasibility trial, and its purpose was not to prove that FREED-M reduces time to treatment or improves clinical outcomes. Qualitative work of this kind answers a different and equally important question: not whether an intervention works, but how it is experienced and which mechanisms plausibly drive its effects. The authors are explicit that the results will be used to inform future iterations of the intervention and its evaluation via a randomized controlled trial, the design that will ultimately determine whether FREED-M changes real-world help-seeking behavior. The feasibility trial itself, with its 72 completers, was a necessary stepping stone toward that larger test, and the interview study adds the explanatory texture that trial statistics alone cannot provide.

Even so, the study arrives at a moment of genuine momentum in early intervention for eating disorders. The work was supported by the National Institute for Health and Care Research under its Research for Patient Benefit scheme, with additional support from the Medical Research Council and partner councils through the EDIFY programme and related networks, and it was delivered through the NIHR Maudsley Biomedical Research Centre. That infrastructure reflects a broader policy recognition that eating disorders are common among young people aged 16 to 25, that delays in help-seeking carry measurable costs in both human and economic terms, and that digital tools may reach people whom traditional services miss. If the planned randomized controlled trial confirms what these young interviewees described, a smartphone intervention that helps them recognize their difficulties, explore them safely, and move toward disclosure and professional support, then FREED-Mobile could become a meaningful bridge between the quiet onset of an eating disorder and the first conversation that begins recovery. For a condition in which every month of delay can deepen the illness, that bridge may prove to be one of the most consequential pieces of software in mental health care.

Subject of Research: Young adults' experiences of using the FREED-Mobile digital intervention to facilitate early help-seeking for eating disorders

Article Title: Young adults’ experiences of using FREED-Mobile, a smartphone friendly intervention designed to facilitate help-seeking for eating disorders

Article References: Potterton, R., Sharpe, H., Allen, K. L., Goldsmith, K., Lawrence, V., Byford, S., Monssen, D., Davies, M. R., Grycuk, L., Prasad, V., Popat, P., Mountford, V., McNeil, S., Grant, N., Glennon, D., Brown, A., & Schmidt, U. (2026). Young adults’ experiences of using FREED-Mobile, a smartphone friendly intervention designed to facilitate help-seeking for eating disorders. Journal of Eating Disorders. https://doi.org/10.1186/s40337-026-01791-8

Image Credits: AI Generated

DOI: 10.1186/s40337-026-01791-8

Keywords: eating disorders, early intervention, FREED-Mobile, digital mental health, help-seeking, young adults, smartphone intervention, reflexive thematic analysis, feasibility trial, psychoeducation, King's College London, Journal of Eating Disorders

The trial, led by Sinead McLernon and colleagues, set out to answer a question that sounds procedural but carries real clinical weight: is it actually possible to embed DIALOG and DIALOG+ in inpatient rehabilitation settings, where patients often have complex and enduring mental health difficulties and where care is delivered by multidisciplinary teams under constant operational pressure? The study was designed not as a test of effectiveness but as a feasibility and acceptability trial, the crucial first step in the pipeline of implementation science. Before a large-scale evaluation can be justified, researchers must establish whether the intervention can be delivered as intended, whether patients and staff will engage with it, and what practical barriers stand in the way. To that end, the team registered their protocol prospectively on ClinicalTrials.gov in May 2024 and received ethical approval from the Health Research Authority in July 2024, following the UK Policy Framework for Health and Social Care research with informed consent from all participants.

Methodologically, the study used a cluster allocation design, meaning that whole wards rather than individual patients were assigned to the implementation conditions. Feasibility data were collected over a five-month intervention period using a deliberately adapted, paper-based format of DIALOG and DIALOG+, a pragmatic choice reflecting the realities of inpatient wards where access to tablets or shared digital devices cannot be assumed. The researchers set pre-established progression criteria, thresholds that would determine whether the study could reasonably advance to a full trial. Staff recruitment and training proved achievable: seventeen staff members were recruited and trained, demonstrating that the service was willing to engage with the research at the organizational level. The patient side of the equation, however, told a different story.

Patient recruitment fell short of the pre-defined progression criteria, and engagement once enrolled was strikingly low. Across the five-month period, the mean number of DIALOG+ sessions completed per patient was just 1.9 out of a planned 10 sessions. Of the eight patients who participated, only four completed more than a single outcome measure. In implementation science terms, these adherence figures signal that the intervention could not be delivered with anything approaching fidelity in this context. The authors are careful to frame these numbers cautiously given the very small sample size, but the pattern is difficult to ignore: a structured monitoring and solution-focused intervention designed to be delivered repeatedly over months was, in practice, delivered once or twice.

To understand why, the researchers turned to qualitative methods. Patient participants completed qualitative surveys about their experiences, while staff participants took part in focus groups and interviews. Thematic analysis of this material identified four overarching themes that shaped whether DIALOG+ could take root. The first concerned staff and stakeholders’ affective attitude towards the feasibility objectives themselves, that is, their emotional responses to what the research was asking of them. The second theme captured affective attitudes towards the intervention, including how staff and patients felt about the DIALOG+ approach on its own merits. The third theme, alignment with current practice, examined whether the tool fitted the existing rhythms and routines of ward life. The fourth and perhaps most revealing theme was the inpatient setting itself, recognizing that the environment imposes constraints that outpatient or community services do not face.

These themes converge on a central insight: the failure was not necessarily one of the intervention’s design but of its integration. The authors identify insufficient adherence and limited integration within multidisciplinary team meetings as key implementation barriers. DIALOG+ is built around the premise that patient-rated outcomes feed directly into care planning conversations, ideally surfacing in the regular reviews where decisions about support are made. When the ratings remain isolated, completed sporadically and discussed outside the team’s main decision-making forums, the mechanism of action is broken. The tool becomes paperwork rather than practice. This finding echoes a broader lesson from implementation research across healthcare: innovations that require changes to team routines need active, sustained support to alter those routines, and simply training individual staff members is rarely enough.

The implications for the wider field of routine outcome monitoring are significant. DIALOG+ has accumulated encouraging evidence in community mental health settings, where structured quality-of-life assessments paired with solution-focused discussions have been associated with improved outcomes. Rehabilitation inpatient wards, however, serve patients with some of the most complex needs in the system, often involving long stays, fluctuating engagement, cognitive and motivational difficulties, and care delivered by shifting combinations of nurses, occupational therapists, psychologists and psychiatrists. The trial suggests that the assumptions about patient throughput and staff continuity that work in community settings may simply not transfer. A patient who is acutely unwell or ambivalent about their care may not reliably complete a ten-session monitoring schedule, however well intentioned the design.

Importantly, the authors do not conclude that DIALOG+ is unsuitable for this population. Instead, they offer concrete directions for future implementation trials: providing dedicated implementation support, additional training, and ongoing supervision to facilitate intervention fidelity and integration into routine multidisciplinary team practice. This recommendation aligns with contemporary implementation frameworks that distinguish between the effort of introducing an intervention and the effort of sustaining it. Dedicated implementation support might include embedding the tool into ward meeting agendas, assigning named staff champions, building completion into care pathways, and providing regular supervision to troubleshoot barriers as they emerge, rather than discovering them at the end of a five-month window.

The study also demonstrates the value of rigorous feasibility methodology itself. By setting progression criteria in advance, registering the trial prospectively, and combining quantitative adherence data with qualitative thematic analysis, the researchers produced a result that is honest and actionable rather than simply disappointing. Many interventions that fail quietly in routine services are never reported, leaving the field to repeat the same mistakes. Publishing a negative feasibility result, with a clear account of the four barrier themes, gives future teams a map of the specific obstacles they must address before investing in a full-scale trial of outcome monitoring in inpatient rehabilitation.

For patients on psychiatric rehabilitation wards, the stakes of getting this right are considerable. Structured monitoring of quality of life has the potential to give voice to people whose preferences are often overlooked in institutional settings, and to convert vague dissatisfaction into specific, solvable problems. The Sheffield-led trial shows that the technology and the clinical logic are portable only up to a point; the surrounding system must carry the intervention, and in this setting it did not. Whether a better-supported, perhaps digitally enabled version of DIALOG+ can succeed where the paper-based approach faltered remains an open question, one that the authors’ recommendations now make possible to test properly. The study, published open access under a Creative Commons licence with support from the University of Sheffield Institutional Open Access Fund, stands as a candid data point in the ongoing effort to make measurement-based mental health care a reality for the patients who need it most.

Subject of Research: Feasibility of implementing the DIALOG+ routine outcome monitoring system in psychiatric rehabilitation inpatient care

Article Title: Is it possible to implement the DIALOG+ routine outcome monitoring system in a psychiatric rehabilitation inpatient setting? A mixed methods feasibility trial in the UK National Health Service

Article References: McLernon, S., Bone, C., Fergusson, A., & Delgadillo, J. (2026). Is it possible to implement the DIALOG+ routine outcome monitoring system in a psychiatric rehabilitation inpatient setting? A mixed methods feasibility trial in the UK National Health Service. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08669-8

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08669-8

Keywords: DIALOG+, routine outcome monitoring, psychiatric rehabilitation, inpatient care, feasibility trial, mixed methods, NHS, implementation science, mental health, quality of life, multidisciplinary team, BMC Psychiatry